Tumores Gastrintestinais
M-A | Ressecção endoscópica vs. cirurgia no tratamento de câncer gástrico inicial.
2 Ago, 2022 | 12:59h
Resultados de longo prazo de um estudo randomizado | Manutenção ativa com olaparibe vs. placebo para câncer pancreático metastático com mutação no BRCA.
1 Ago, 2022 | 15:08hOverall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B
— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022
Estudo randomizado fase 2 | Eficácia de mFOLFIRINOX pré-operatório vs. mFOLFIRINOX com radioterapia hipofracionada para adenocarcinoma ressecável limítrofe do pâncreas.
18 Jul, 2022 | 13:16hEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)
Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Preoperative combination chemotherapy improved survival in patients with pancreatic cancer – The University of Texas MD Anderson Cancer Center
Comentário no Twitter
Ph 2 trial of 126 pts w/borderline resectable pancreatic ductal adenoCa shows 18 mo OS after neoadjuvant mFOLFIRINOX of 66.7%, favorable vs. historical data; 18m OS if mFOLFORINOX then hypofract RT is 47.3%, if chemo then pancreatectomy is 87.5%. https://t.co/wOMNrTOAzm
— JAMA Oncology (@JAMAOnc) July 14, 2022
Estudo randomizado transversal | Inteligência artificial (IA) reduz a taxa de falha no achado de pólipos pré-cancerosos no rastreamento de câncer colorretal.
18 Jul, 2022 | 12:41hComunicado de imprensa: AI reduces miss rate of precancerous polyps in colorectal cancer screening – Mayo Clinic
Estudo original: Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia – Gastroenterology
M-A | Risco de desenvolvimento de câncer de vesícula biliar em pacientes com pólipos vesiculares detectados em ultrassonografia transabdominal.
18 Jul, 2022 | 12:30hRisk of developing gallbladder cancer in patients with gallbladder polyps detected on Trans-Abdominal ultrasound: a systematic review and Meta-Analysis – British Journal of Radiology (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps – Annals of Surgical Oncology (se o acesso a este link for pago, tente este)
Estudo randomizado | Cabozantinibe com atezolizumabe vs. sorafenibe para carcinoma hepatocelular avançado.
11 Jul, 2022 | 13:45hComentário convidado: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (necessário cadastro gratuito)
Comentário no Twitter
In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr
— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022
Estudo de rastreamento multicêntrico de câncer de pâncreas: impacto sobre estágio e sobrevida.
6 Jul, 2022 | 10:54h
Comentário no Twitter
👀 The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022